泮托拉唑对比奥美拉唑治疗胃溃疡的成本效果分析
|
摘要
目的:运用药物经济学方法研究和评价泮托拉唑对比奥美拉唑治疗胃溃疡的成本效果,为临床合理用药提供参考和建议。方法:立足医疗系统研究视角,构建决策树模型对泮托拉唑和奥美拉唑治疗胃溃疡进行成本效果分析,并对参数的不确定性进行单因素敏感性分析。结果:从平均成本效果比来看,泮托拉唑治疗胃溃疡平均每单位效果的成本为33. 36元,奥美拉唑为21. 18元;增量成本效果分析显示,泮托拉唑相对于奥美拉唑的增量成本效果比为131. 14(ICER=131. 14),增加单位治愈病例意愿支付金额小于131. 14元时,最优方案为奥美拉唑,意愿支付金额大于131. 14元时,最优方案为泮托拉唑。结论:临床医生可以根据胃溃疡患者意愿支付金额高低选择最优的治疗方案。
Objective: To study and evaluate the cost-effectiveness of pantoprazole versus omeprazole in the treatment of gastric ulcer by pharmacoeconomic methods,and to provide reference and suggestions for rational drug use in clinic. Methods: From the perspective of medical system,a decision tree model was established to analyze the cost-effectiveness of pantoprazole and omeprazole in the treatment of gastric ulcer,and the uncertainty of parameters was analyzed by single factor sensitivity analysis. Results: From the average cost-effectiveness ratio,the average cost per unit effect of pantoprazole in the treatment of gastric ulcer was 33. 36 yuan and that of omeprazole was21. 18 yuan. Incremental cost-effectiveness analysis showed that the incremental cost-effectiveness ratio of pantoprazole to omeprazole was131. 14( ICER = 131. 14). When the unit willingness to pay was less than 131. 14 yuan,the optimal scheme was omeprazole. When the willingness to pay is more than 131. 14 yuan,pantoprazole is the better option. Conclusion: Clinicians can choose the optimal treatment plan according to the amount of money which patient willing to pay for gastric ulcer.
Objective: To study and evaluate the cost-effectiveness of pantoprazole versus omeprazole in the treatment of gastric ulcer by pharmacoeconomic methods,and to provide reference and suggestions for rational drug use in clinic. Methods: From the perspective of medical system,a decision tree model was established to analyze the cost-effectiveness of pantoprazole and omeprazole in the treatment of gastric ulcer,and the uncertainty of parameters was analyzed by single factor sensitivity analysis. Results: From the average cost-effectiveness ratio,the average cost per unit effect of pantoprazole in the treatment of gastric ulcer was 33. 36 yuan and that of omeprazole was21. 18 yuan. Incremental cost-effectiveness analysis showed that the incremental cost-effectiveness ratio of pantoprazole to omeprazole was131. 14( ICER = 131. 14). When the unit willingness to pay was less than 131. 14 yuan,the optimal scheme was omeprazole. When the willingness to pay is more than 131. 14 yuan,pantoprazole is the better option. Conclusion: Clinicians can choose the optimal treatment plan according to the amount of money which patient willing to pay for gastric ulcer.
引文
[1]刘宇宏,王世鑫.近年来质子泵抑制剂的研究进展[J].中国新药杂志,2001,10(3):161-164.
[2]Kusano M.A review of the management of gastric acid-related diseases:Focus on rabeprazole[J].Clinical Medicine Insights:Gastroenterology,2011,3(4):31-43.
[3]Stedman C A M,Barclay M L.Review article:comparison of the pharmacokinetics,acid suppression and efficacy of proton pump inhibitors[J].Aliment Pharmacol Ther,2000,14(8):963-978.
[4]中华医学会:临床诊疗指南:消化系统疾病分册[M].北京:人民卫生出版社,2004:32-34.
[5]孙向南.胃溃疡疾病采用泮托拉唑与奥美拉唑治疗的效果分析[J].世界最新医学信息文摘,2017,17(53):106-107.
[6]梁君铭,骆雪梅.泮托拉唑和奥美拉唑治疗胃溃疡的疗效对比分析[J].现代诊断与治疗,2015,(7):1502-1503.
[7]刘中宏,王秀江,马香华.泮托拉唑与奥美拉唑治疗胃溃疡的疗效观察[J].中国基层医药,2002,9(2):111-112.
[8]栗红梅.泮托拉唑和奥美拉唑治疗胃溃疡的疗效对比[J].大家健康(学术版),2016,10(2):131-132.
[9]王慧.泮托拉唑与奥美拉唑治疗胃溃疡的效果对比评估及观察[J].中国现代药物应用,2016,10(5):104-105.
[10]肖胜伦.泮托拉唑与奥美拉唑治疗胃溃疡的效果和安全性比较[J].中华临床医师杂志(电子版),2016,(6):220.
[11]董桂君,巨森,赵平,等.评价泮托拉唑对比奥美拉唑治疗胃溃疡的效果和安全性[J].临床检验杂志(电子版),2017,6(2):240.
[12]witzel L,gütz H,hüttemann W,et al.Pantoprazole versus omeprazole in the treatment of acute gastric ulcers.[J].Aliment Pharmacol Ther,1995,9(1):19-24.
[13]住友靖彦.质子泵抑制剂(PPI)的适应证[J].日本医学介绍,2002,23(1):25-26.
[14]Barth J,Hahne W.Review article:rabeprazole-based therapy in Helicobacter pylori eradication[J].Aliment Pharmacol Ther,2002,16(1):31-33.
[15]马丽群.质子泵抑制剂的研究和临床应用进展[J].内科,2012,7(2):160-163.
[16]叶玲梅,蔡咏梅.质子泵抑制剂的不良反应及防治对策[J].中国药房,2011,22(8):760-761.
[17]付振强.系统评价泮托拉唑对比奥美拉唑治疗胃溃疡的效果和安全性[J].中外医学研究,2016,14(05):112-113.
[2]Kusano M.A review of the management of gastric acid-related diseases:Focus on rabeprazole[J].Clinical Medicine Insights:Gastroenterology,2011,3(4):31-43.
[3]Stedman C A M,Barclay M L.Review article:comparison of the pharmacokinetics,acid suppression and efficacy of proton pump inhibitors[J].Aliment Pharmacol Ther,2000,14(8):963-978.
[4]中华医学会:临床诊疗指南:消化系统疾病分册[M].北京:人民卫生出版社,2004:32-34.
[5]孙向南.胃溃疡疾病采用泮托拉唑与奥美拉唑治疗的效果分析[J].世界最新医学信息文摘,2017,17(53):106-107.
[6]梁君铭,骆雪梅.泮托拉唑和奥美拉唑治疗胃溃疡的疗效对比分析[J].现代诊断与治疗,2015,(7):1502-1503.
[7]刘中宏,王秀江,马香华.泮托拉唑与奥美拉唑治疗胃溃疡的疗效观察[J].中国基层医药,2002,9(2):111-112.
[8]栗红梅.泮托拉唑和奥美拉唑治疗胃溃疡的疗效对比[J].大家健康(学术版),2016,10(2):131-132.
[9]王慧.泮托拉唑与奥美拉唑治疗胃溃疡的效果对比评估及观察[J].中国现代药物应用,2016,10(5):104-105.
[10]肖胜伦.泮托拉唑与奥美拉唑治疗胃溃疡的效果和安全性比较[J].中华临床医师杂志(电子版),2016,(6):220.
[11]董桂君,巨森,赵平,等.评价泮托拉唑对比奥美拉唑治疗胃溃疡的效果和安全性[J].临床检验杂志(电子版),2017,6(2):240.
[12]witzel L,gütz H,hüttemann W,et al.Pantoprazole versus omeprazole in the treatment of acute gastric ulcers.[J].Aliment Pharmacol Ther,1995,9(1):19-24.
[13]住友靖彦.质子泵抑制剂(PPI)的适应证[J].日本医学介绍,2002,23(1):25-26.
[14]Barth J,Hahne W.Review article:rabeprazole-based therapy in Helicobacter pylori eradication[J].Aliment Pharmacol Ther,2002,16(1):31-33.
[15]马丽群.质子泵抑制剂的研究和临床应用进展[J].内科,2012,7(2):160-163.
[16]叶玲梅,蔡咏梅.质子泵抑制剂的不良反应及防治对策[J].中国药房,2011,22(8):760-761.
[17]付振强.系统评价泮托拉唑对比奥美拉唑治疗胃溃疡的效果和安全性[J].中外医学研究,2016,14(05):112-113.